Literature DB >> 10798038

Kala-azar--new developments in diagnosis and treatment.

P Aggarwal1, R Handa, S Singh, J P Wali.   

Abstract

Kala-azar is an endemic disease in many parts of India. Traditionally, diagnosis of this disease was based on demonstrating the parasites in various tissues like bone marrow or splenic aspirates. However, lack of high sensitivity of these methods led to the use of various immunodiagnostic methods in the diagnosis of kala-azar. Antigen detection and polymerase chain reaction to detect parasitic DNA have been found to be useful in patients with an underlying immunosuppressive disease like AIDS. For treating kala-azar, pentavalent antimonial compounds are still the first-line agents. However, due to increasing resistance to this agent, many patients at present require other drugs including amphotericin B and pentamidine. Toxic effects of these second-line agents have led to development of drug delivery systems like liposomal amphotericin B, which has shown uniform efficacy in clinical trials. Combining stibogluconate with either paromomycin or interferon-gamma has also been shown to be useful in many patients with drug-resistant kala-azar.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10798038     DOI: 10.1007/bf02752355

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  26 in total

1.  Enzyme-linked immunosorbent assay in the diagnosis of kala-azar in Bhadohi (Varanasi), India.

Authors:  A Choudhry; P Y Guru; R P Saxena; A Tandon; K C Saxena
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 May-Jun       Impact factor: 2.184

2.  Serological diagnosis of visceral leishmaniasis by a dot-enzyme immunoassay for the detection of a Leishmania donovani-related circulating antigen.

Authors:  G Senaldi; H Xiao-su; D C Hoessli; C Bordier
Journal:  J Immunol Methods       Date:  1996-06-14       Impact factor: 2.303

3.  Direct agglutination test for early diagnosis of Indian visceral leishmaniasis.

Authors:  T K Jha; C P Thakur; I J Singh; T K Singh; S Jha
Journal:  J Assoc Physicians India       Date:  1996-09

4.  Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar--a comparative study.

Authors:  J P Wali; P Aggarwal; A Nandy; S Singh; M Addy; S K Guha; S N Dwivedi; M G Karmarkar; A K Maji
Journal:  J Commun Dis       Date:  1997-06

5.  Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.

Authors:  C P Thakur; A K Pandey; G P Sinha; S Roy; K Behbehani; P Olliaro
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 May-Jun       Impact factor: 2.184

6.  Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis.

Authors:  S Singh; A Gilman-Sachs; K P Chang; S G Reed
Journal:  J Parasitol       Date:  1995-12       Impact factor: 1.276

Review 7.  Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies.

Authors:  B L Herwaldt; J D Berman
Journal:  Am J Trop Med Hyg       Date:  1992-03       Impact factor: 2.345

8.  Anti-66 kDa antileishmanial antibodies as specific immunodiagnostic probe for visceral leishmaniasis.

Authors:  V K Vinayak; D Mahajan; R C Sobti; N Singla; S Sundar
Journal:  Indian J Med Res       Date:  1994-03       Impact factor: 2.375

9.  Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial.

Authors:  C P Thakur; S Bhowmick; L Dolfi; P Olliaro
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Mar-Apr       Impact factor: 2.184

10.  Standardization of the dot enzyme-linked immunosorbent assay (Dot-ELISA) for human visceral leishmaniasis.

Authors:  M G Pappas; R Hajkowski; W T Hockmeyer
Journal:  Am J Trop Med Hyg       Date:  1984-11       Impact factor: 2.345

View more
  5 in total

1.  Characterization of the gene encoding glyoxalase II from Leishmania donovani: a potential target for anti-parasite drugs.

Authors:  Prasad K Padmanabhan; Angana Mukherjee; Rentala Madhubala
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion.

Authors:  Mireille Basselin; Hubert Denise; Graham H Coombs; Michael P Barrett
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

3.  High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay.

Authors:  Swati Mandal; Mahendra Maharjan; Sudipto Ganguly; Mitali Chatterjee; Sarman Singh; Frederick S Buckner; Rentala Madhubala
Journal:  Indian J Exp Biol       Date:  2009-06       Impact factor: 0.818

4.  In vitro growth inhibitory activity of Medicines for Malaria Venture pathogen box compounds against Leishmania aethiopica.

Authors:  Markos Tadele; Solomon M Abay; Peter Asaga; Eyasu Makonnen; Asrat Hailu
Journal:  BMC Pharmacol Toxicol       Date:  2021-11-16       Impact factor: 2.483

5.  Leishmania donovani Growth Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture.

Authors:  Markos Tadele; Solomon M Abay; Eyasu Makonnen; Asrat Hailu
Journal:  Drug Des Devel Ther       Date:  2020-03-31       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.